Bactrim Ds

Shigellosis, Nocardiosis, Brucellosis + 16 more

Treatment

17 FDA approvals

16 Active Studies for Bactrim Ds

What is Bactrim Ds

Trimethoprim

The Generic name of this drug

Treatment Summary

Sulfamethoxazole is an antibiotic used to treat bacterial infections. It works by blocking the bacteria's ability to create folic acid, an important component for growth. When used with trimethoprim, it is effective in treating urinary tract infections, respiratory infections, and gastrointestinal infections.

Septra DS

is the brand name

image of different drug pills on a surface

Bactrim Ds Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Septra DS

Trimethoprim

1973

343

Approved as Treatment by the FDA

Trimethoprim, also called Septra DS, is approved by the FDA for 17 uses including Cholera and susceptible Enteritis infectious caused by Shigella sonnei .

Cholera

Used to treat susceptible Cholera in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella sonnei

Used to treat susceptible Enteritis infectious caused by Shigella sonnei in combination with Sulfamethoxazole

Fluid replacement therapy

Used to treat Fluid replacement therapy in combination with Sulfamethoxazole

Urinary tract infection

Used to treat Urinary Tract Infection caused by susceptible bacteria in combination with Sulfamethoxazole

Nocardiosis

Used to treat Nocardiosis in combination with Sulfamethoxazole

Pneumonia, Pneumocystis

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Genus Pneumocystis

Used to treat risk of Pneumocystis jiroveci pneumonia (PCP) in combination with Sulfamethoxazole

Otitis Media

Used to treat Acute Otitis Media caused by susceptible bacteria in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Electrolyte replacement

Used to treat Electrolyte replacement in combination with Sulfamethoxazole

Pneumocystis Jirovecii Pneumonia

Used to treat Pneumocystis Jirovecii Pneumonia in combination with Sulfamethoxazole

Shigellosis

Used to treat Dysentery, Bacillary in combination with Sulfamethoxazole

Bronchitis

Used to treat Acute Exacerbation of Chronic Bronchitis (AECB) caused by susceptible bacteria in combination with Sulfamethoxazole

Diarrhea

Used to treat susceptible Travelers' Diarrhea caused by Enterotoxigenic E. Coli (ETEC) Infection in combination with Sulfamethoxazole

susceptible Enteritis infectious caused by Shigella flexneri

Used to treat susceptible Enteritis infectious caused by Shigella flexneri in combination with Sulfamethoxazole

Brucellosis

Used to treat Brucellosis in combination with Rifampicin

Immunocompromised

Used to treat Immunocompromised in combination with Sulfamethoxazole

Effectiveness

How Bactrim Ds Affects Patients

Sulfamethoxazole is an antibiotic used to fight bacteria. It is most often used in combination with another antibiotic called trimethoprim, as this prevents bacteria from developing a resistance to the treatment. However, sulfamethoxazole can cause allergic reactions, ranging from mild rashes to severe reactions like Stevens-Johnson syndrome or toxic epidermal necrolysis. It can also cause folate deficiency in some people, and can lead to hemolysis (breakdown of red blood cells) in people with glucose-6-phosphate dehydrogenase deficiency.

How Bactrim Ds works in the body

Sulfamethoxazole is a medication that works to stop bacteria from reproducing. It does this by blocking the enzyme responsible for converting a compound found in bacteria into folic acid, which is essential for bacterial growth. When the enzyme is blocked, the bacteria can't produce the folic acid needed for them to reproduce, resulting in a slowdown of their growth.

When to interrupt dosage

The prescribed dosage of Bactrim Ds is contingent upon the determined issue, including Urinary tract infection, Pneumocystis Jirovecii Pneumonia and Fluid replacement therapy. The amount of dosage is contingent upon the administration process outlined in the table hereunder.

Condition

Dosage

Administration

Conjunctivitis, Bacterial

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Pneumonia, Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Brucellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Immunocompromised

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Nocardiosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

bacterial blepharitis caused by susceptible bacteria

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Urinary tract infection

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Diarrhea

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Shigellosis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Electrolyte replacement

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Fluid replacement therapy

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Genus Pneumocystis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Bacterial conjunctivitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Bronchitis

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

susceptible Enteritis infectious caused by Shigella flexneri

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

susceptible Enteritis infectious caused by Shigella sonnei

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Otitis Media

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Cholera

, 1.0 mg/mL, 160.0 mg, 80.0 mg, 40.0 mg/mL, 50.0 mg/mL, 100.0 mg, 0.16 mg, 1.6 mg, 20.0 mg, 200.0 mg, 90.0 mg, 16.0 mg/mL, 300.0 mg, 40.0 mg, 8.0 mg/mL, 9.0 mg/mL

Solution / drops - Ophthalmic, , Ophthalmic, Tablet - Oral, Oral, Tablet, Solution, Solution - Oral, Solution - Ophthalmic, Suspension - Oral, Suspension, Injection, solution, concentrate - Intravenous, Solution - Intravenous, Intravenous, Solution / drops, Liquid - Ophthalmic, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection - Intravenous, Injection

Warnings

Bactrim Ds has seven contraindications. Under no circumstances should it be utilized alongside the conditions provided in the following table.

Bactrim Ds Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

Purpura, Thrombocytopenic, Idiopathic

Do Not Combine

hepatic damage

Do Not Combine

Megaloblastic anemia caused by Folate deficiency

Do Not Combine

unable to monitor renal function

Do Not Combine

Disease

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Trimethoprim may interact with Pulse Frequency

There are 20 known major drug interactions with Bactrim Ds.

Common Bactrim Ds Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Trimethoprim.

Brigatinib

Major

The metabolism of Brigatinib can be decreased when combined with Trimethoprim.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Trimethoprim.

Cisplatin

Major

The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.

Clofarabine

Major

The serum concentration of Clofarabine can be increased when it is combined with Trimethoprim.

Bactrim Ds Toxicity & Overdose Risk

The toxic dose of sulfamethoxazole in mice and rats is 2300mg/kg and 6200mg/kg respectively. Symptoms of overdose include loss of appetite, stomach pain, nausea, vomiting, dizziness, headache, drowsiness, and loss of consciousness. Other less common symptoms may include fever, blood in the urine, and formation of crystals in the urine. Later on, the patient may experience issues with their blood count and develop jaundice. Treatment should address the symptoms and may include cleaning the stomach or inducing vomiting. Lab tests should also be conducted to check for any issues with the blood or electrolytes

image of a doctor in a lab doing drug, clinical research

Bactrim Ds Novel Uses: Which Conditions Have a Clinical Trial Featuring Bactrim Ds?

8 active clinical trials are being conducted to explore the use of Bactrim Ds in Immunocompromised patients, Fluid replacement therapy and the treatment of susceptible Enteritis infections caused by Shigella sonnei.

Condition

Clinical Trials

Trial Phases

Urinary tract infection

0 Actively Recruiting

Bacterial conjunctivitis

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Nocardiosis

0 Actively Recruiting

Shigellosis

0 Actively Recruiting

Brucellosis

0 Actively Recruiting

bacterial blepharitis caused by susceptible bacteria

0 Actively Recruiting

Immunocompromised

2 Actively Recruiting

Phase 1, Not Applicable

Otitis Media

0 Actively Recruiting

Genus Pneumocystis

0 Actively Recruiting

Conjunctivitis, Bacterial

0 Actively Recruiting

Fluid replacement therapy

0 Actively Recruiting

Cholera

0 Actively Recruiting

Urinary tract infection

0 Actively Recruiting

susceptible Enteritis infectious caused by Shigella sonnei

0 Actively Recruiting

Pneumonia, Pneumocystis

2 Actively Recruiting

Phase 3, Phase 4

susceptible Enteritis infectious caused by Shigella flexneri

0 Actively Recruiting

Electrolyte replacement

0 Actively Recruiting

Diarrhea

12 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 1

Bactrim Ds Reviews: What are patients saying about Bactrim Ds?

5

Patient Review

9/5/2021

Bactrim Ds for Urinary Tract Infection Prevention

I'm a teacher and got a UTI from not being able to use the restroom during the day. I'm 51 years old and had no problems taking this medication. Our bodies can react differently to medications, so I think it's important to keep that in mind when reading reviews like this. The infection was really bad (there was blood in my urine), so I received an antibiotic shot first, and then this oral antibiotic. In just three days, I felt almost back to normal.

5

Patient Review

9/23/2022

Bactrim Ds for infection

I'm using this medication to treat cellulitis on my arm and so far I haven't noticed any negative side effects.

5

Patient Review

4/3/2020

Bactrim Ds for Skin Infection

This cleared up the infection in my hand quickly and effectively.

4

Patient Review

8/22/2019

Bactrim Ds for Urinary Tract Infection due to E. Coli Bacteria

Bactrim DS is a great drug. I have allergies to many antibiotics, but this one was gentle enough for me. The worst side effects I felt were tiredness and a headache, but both went away after the first few days. This antibiotic cleared my UTI infection after just two days. It works quickly and is very potent. I would recommend it to anyone who is sensitive to antibiotics like me. You can be put on a 5 day regimen and be cured with this antibiotic.

4

Patient Review

9/18/2022

Bactrim Ds for Skin Infection

Bactrim was a very effective antibiotic for me, and I experienced few negative side effects. The only issue I had was that the pills were extremely large.

2.7

Patient Review

8/26/2020

Bactrim Ds for infection

I'm not a fan of this medication. It's 1:30 in the morning and my jaw is killing me. I feels like it's stuck shut, and my arms are very sensitive. I feel weak and dizzy, and this feeling has lasted for days.

2

Patient Review

11/12/2019

Bactrim Ds for Pneumonia caused by Bacteria

I had an allergic reaction to this drug that was very severe. I almost had to go to the emergency room because of it. Make sure you tell your doctor about any side effects you experience.

1.7

Patient Review

10/1/2022

Bactrim Ds for Bacterial Urinary Tract Infection

Do your best to steer clear of this antibiotic. It caused me immense nausea and diarrhea within the first week, to the point where I had to take Gravol just to make it through the day. Additionally, it made me feel exhausted and my heart rate was all over the place.

1.7

Patient Review

8/20/2020

Bactrim Ds for infection

I experienced a lot of the potential side effects while taking this medication and it was honestly pretty scary.

1

Patient Review

2/2/2021

Bactrim Ds for Infection of Urinary Tract due to Enterobacter Cloacae

This drug is dangerous and webmd needs to do a better job of really Listing and checking the facts. Muscle weakness Lethargic overtired unable to get up and move loss of appetite and nausea. This Was BANNED in the UK and clinical studies show prolonged use compromises your immune system and the older you are the higher mortality rate when using! Update the true facts webmd or are you paid for big big pharma. The research is out there people this drug should be removed from usage.

1

Patient Review

10/27/2022

Bactrim Ds for Skin Infection

BEWARE! This can burn the scrap out of your skin. Anyone allergic to sulfur beware! And, if you are not sure do NOT use this product. AVOID THIS PRODUCT !

1

Patient Review

8/11/2022

Bactrim Ds for Urinary Tract Infection Prevention

Unfortunately, this medication caused me to shake uncontrollably all over my body. I won't be taking it again.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bactrim ds

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the side effects of Bactrim DS?

", or any other sign that your body is not tolerating campath

If you experience any of the following side effects, call your doctor immediately: severe stomach pain, watery or bloody diarrhea (even if it occurs months after your last dose), a skin rash (even if it is mild), yellowing of your skin or eyes, a seizure, new or unusual joint pain, increased or decreased urination, swelling, bruising, or irritation around the IV needle, or any other sign that your body is not tolerating campath."

Answered by AI

What is bactrim ds used to treat?

"This medication is a combination of two antibiotics, sulfamethoxazole and trimethoprim. It can be used to treat a number of bacterial infections, such as those in the middle ear, respiratory system and intestine, as well as preventing and treating pneumocystis pneumonia."

Answered by AI

What is the difference between Bactrim and Bactrim DS?

"Bactrim is available in two tablet strengths: 400 mg sulfamethoxazole and 80 mg trimethoprim, and the "DS" form, which is double strength (800 mg sulfamethoxazole and 160 mg trimethoprim). Patients should follow their doctor's instructions and take all of the Bactrim prescribed."

Answered by AI

Is Bactrim DS a strong antibiotic?

"Bactrim is a powerful combination antibiotic, but it may not be appropriate for people with kidney or liver disease, or who are deficient in folate. The elderly are at a higher risk of experiencing side effects."

Answered by AI

Clinical Trials for Bactrim Ds

Image of McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital in Montreal, Canada.

Systemic Corticosteroids for Pneumocystis Pneumonia

18+
All Sexes
Montreal, Canada

The HOW LONG trial is an international, multicenter, Phase IV randomized clinical trial evaluating the optimal duration of adjunctive systemic corticosteroids in immunocompromised adults with severe Pneumocystis jirovecii pneumonia (PCP) who demonstrate early clinical recovery. Participants who no longer require supplemental oxygen by day 10 of corticosteroid therapy are randomized to discontinue corticosteroids at day 10 (or hospital discharge, if earlier) versus continue corticosteroids for a total of 21 days. The trial assesses whether earlier discontinuation reduces steroid-related complications while maintaining clinical outcomes.

Phase 4
Waitlist Available

McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Bactrim Ds clinical trials?

We made a collection of clinical trials featuring Bactrim Ds, we think they might fit your search criteria.
Go to Trials
Image of University of Maryland, School of Medicine, Center for Vaccine Development and Global Health in Baltimore, United States.

Vaccine for E. coli Infections

18 - 49
All Sexes
Baltimore, MD

The study is designed to evaluate the safety, immunogenicity, and efficacy of the intramuscular administration of a CS6 based vaccine (CssBA) against ETEC co-administered with double mutant labile toxin (dmLT) in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. Approximately 72 adult participants, divided into 4 cohorts of 18, will be randomized 1:1 to receive vaccine (45 micrograms CssBA with 0.5 micrograms dmLT) or placebo (normal saline) on an outpatient basis. All participants will receive 3 intramuscular (IM) doses of vaccine or placebo at 3-week intervals (days 1, 22 and 43). Following vaccination, participants will be followed as outpatients for safety using a memory aid from the time of each vaccination through 7 days post each vaccination. Approximately 28 days (plus or minus 1 day) after receipt of the 3rd dose of study agent, participants meeting challenge criteria will be admitted to an inpatient unit and be administered an oral dose of 1 x 10\^10 cfu (colony-forming unit) of ETEC strain B7A. Five days after challenge, participants will be treated with ciprofloxacin, except in cases of known allergy or intolerance. Participants will be discharged from the inpatient unit when they have completed their 3-day antibiotic course and are able to care for themselves. After discharge from the inpatient unit, participants will return for clinic visits and have a phone visit to provide any updates on medication, medical history and AE/SAEs. The primary objectives are: 1) Estimate CssBA+dmLT efficacy in preventing moderate-severe diarrhea (MSD) following challenge with ETEC strain B7A in healthy adults. 2) Evaluate the safety of intramuscular injection of CssBA+dmLT.

Phase 2
Waitlist Available

University of Maryland, School of Medicine, Center for Vaccine Development and Global Health (+1 Sites)

Have you considered Bactrim Ds clinical trials?

We made a collection of clinical trials featuring Bactrim Ds, we think they might fit your search criteria.
Go to Trials
Image of McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) in Montreal, Canada.

Low-Dose Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia

18 - 100
All Sexes
Montreal, Canada

Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection of immunocompromised hosts which causes in significant morbidity and mortality. The current standard of care, trimethoprim-sulfamethoxazole (TMP-SMX) at a dose of 15-20 mg/kg/day of TMP, is associated with serious adverse events, including hypersensitivity reactions, drug-induced liver injury, cytopenia, and renal failure occurring among 20-60% of patients. The frequency of adverse events increases in a dose dependent manner and commonly limits the use of TMP-SMX. Reduced treatment doses of TMP-SMX for PJP reduced ADEs without mortality differences in a recent meta-analysis of observational studies. We therefore propose a Phase III randomized, placebo-controlled trial to directly compare the efficacy and safety of low dose (10 mg/kg/day of TMP) compared to the standard-of-care (15 mg/kg/day) among patients with PJP for the primary outcome of death, new mechanical ventilation, and change of treatment.

Phase 3
Waitlist Available

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Emily G McDonald, MD MSc

Have you considered Bactrim Ds clinical trials?

We made a collection of clinical trials featuring Bactrim Ds, we think they might fit your search criteria.
Go to Trials